## **Department of Clinical Laboratory Genetics**

## **Genome Diagnostics & Cancer Cytogenetics** Malignant Hematology Testing

## **Toronto General Hospital**

Eaton Wing 11-444, 200 Elizabeth Street

Toronto, Ontario M5G 2C4

Head: Tracy Stockley, PhD, FCCMG, FACMG

Phone: (416) 340-4800 x5739

Fax: (416) 340-3596 Cancer Cytogenetics Fax: (416) 340-4473 Genome Diagnostics

Email: Genome.diagnostics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

Patient Information or Hospital Stamp Here Last Name:
First Name:
Date of Birth (MM/DD/YYYY):
Sex:
Health Card #:
Hospital #:

#### Instructions:

THIS REQ IS FOR MALIGNANT HEMATOLOGY TESTING ONLY - see link at bottom of page for SOLID TUMOUR Full Name of Referring Physician and HEREDITARY requisitions.

- 1.Complete all information as requested
- 2. Send requisition with specimen to address above

### DO NOT COME TO TORONTO GENERAL FOR **BLOOD DRAW**

- 3. Keep specimen at room temperature unless
- 4.If shipping, send same day or next day delivery

## **Information For Reporting:**

Physician Billing # Hospital/Address:

Phone: Fax:

Physician Signature:

5.Specimen labelling: <b>Name, DOB, MRN#, Date</b>	Copy Report To:	
Taken		

## Specimen Requirements – Genome **Diagnostics:**

Peripheral blood

For leukemia/lymphoma - 20 mL in EDTA For circulating tumour (cell free DNA) - 18 ml in STRECK tubes For all other testing - 5ml in EDTA

Bone marrow aspirate

1-2 ml in EDTA

Extracted DNA or RNA (>1µg)	(please circle nucleic acid)
Tissue Source	

Concentration: Volume:

Extracted nucleic acid will only be accepted from an appropriately accredited laboratory (ex.IQMH or equivalent).

## Specimen Requirements – Cytogenetics (Page 3):

☐ Bone marrow aspirate >1.5 ml in sodium heparin

☐Peripheral blood 5-10 ml in sodium heparin

#### ☐ Paraffin Embedded Tissue (FISH)

- -include circled H&E
- -2 x 4μm sections/probe on positively charged slides, air dried

## □Cytology preparation (FISH)

- -Air-dried smear/touch prep (1-2 per test)
- -Cytospin slide (1-2 per test)

N.B. Currently, decalcified specimens cannot be reported clinically.

Please ensure that you are using an updated copy of this requisition available at:



#### **Department of Clinical Laboratory Genetics**

Genome Diagnostics & Cancer Cytogenetics - Malignant Hematology

ivialignant nematology

#### **Toronto General Hospital**

Eaton Wing 11-444, 200 Elizabeth Street

Toronto, Ontario M5G 2C4

Head: Tracy Stockley, PhD, FCCMG, FACMG Phone: (416) 340-4800 x5739 FAX: (416) 340-4473

Email: Genome.diagnostics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

Patient Information or Hospital Stamp Here Last Name:
First Name:
Date of Birth (MM/DD/YYYY):
Sex:
Health Card #:
Hospital #:

Clinical Diagnosis/Reason for		
Referral: ☐ Diagnosis:	☐ Monitoring: (for follow-up samples)  Treatment (specify type)	
☐ Other:	Date of last treatment	

## **Genome Diagnostics Tests - Hematological**

		•
	kem	12.
LCU	KCIII	ıa.

- □ ^BCR::ABL1 t(9;22)
  - Please indicate if known CML or ALL
- □ ^ABL1 kinase domain mutation
  - Please indicate breakpoint if known p210 or p190
- □ ^RUNX1::RUNX1T1 (AML/ETO) t(8;21)
- □ ^CBFB::MYH11 Inv(16) or t(16;16)
- □ ^PML::RARA t(15;17)
- ☐ FLT3/NPM1 (newly diagnosed AML)
- ☐ FLT3 only (relapsed/refractory AML)
- ^ NPM1 MRD (4bp insertion between nucleotide 863 and 864 only)
- ☐ CLL IGHV Somatic Hypermutation/TP53 (for patients requiring treatment only)

## **Malignant Hematology NGS panel:**

Funded for AML, MPN, MDS, and MDS/MPN. Please provide supporting documentation for testing. If molecular profiling was previously performed at another institution, please provide molecular results.

☐ Comprehensive Sequencing (NGS), includes:

ASXL1	CUX1	GNAS	KRAS	PTPN11	TP53
BCOR	DDX41	IDH1	MPL	RAD21	U2AF1
BCORL1	DNMT3A	IDH2	MYD88	RUNX1	WT1
BRAF	ETNK1	IKZF1	NOTCH1	SETBP1	ZRSR2
CALR	ETV6	IRF1	NPM1	SF3B1	
CBL	EZH2	JAK1	NRAS	SH2B3	
CEBPA	FBXW7	JAK2	PAX5	SRSF2	
CSF3R	FLT3	KIT	PHF6	STAG2	
CTNNA1	GATA2	KMT2A	PPM1D	TET2	

# Lymphoma: please attach corresponding pathology report

- ☐ ^B-cell Clonality
- □ ^T-cell Clonality
- □ ^MYD88

## Bone marrow/Stem cell transplant monitoring:

□ ^15 STRs and amelogenin XY loci

#### Please specify:

- ☐ Donor
- ☐ Recipient Pre-SCT
- ☐ Recipient Post-SCT (Split Chimerism)

#### Other:

- □^BRAF (p.V600E/K only) (please select: Hairy cell leukemia, Langerhans cell histiocytosis, Erdheim-Chester)
- □^KIT (Mastocytosis BM or involved tissue preferred)
- □^JAK2 (Exon 12 + Exon 14 p.V617F) / CALR (MPD)

# Identity Testing (15 STRs and amelogenin XY loci):

□ ^Specimen matching (Please provide control specimen, specimen in question and details)

^Indicates a test that will be billed to the referring hospital, laboratory, physician or medical group.

Page 2/3 Version 8.2 Dec 2022



### Department of Clinical Laboratory Genetics Genome Diagnostics & Cancer Cytogenetics -Malignant Hematology Testing

#### **Toronto General Hospital**

Eaton Wing 11-444, 200 Elizabeth Street Toronto, Ontario M5G 2C4

Head: Tracy Stockley, PhD, FCCMG, FACMG

Phone: (416) 340-4800 x5739 FAX: (416) 340-3596

Email: cancercytogenetics@uhn.ca

Hours of Operation (Mon-Fri) 8:30AM-4:30PM

CAP: 7175217 CLIA: 99D1106115 IQMH: 4204-site 0141

**Clinical Diagnosis/Reason for Referral**:

Patient Information or Hospital Stamp Here Last Name:
First Name:
Date of Birth (MM/DD/YYYY):
Sex:
Health Card #:
Hospital #:

Treatment (specify type) \_

A bone marrow report must accompany or be sent by fax/email for all bone marrow samples. All samples will be banked and testing delayed until this information is received.

☐ Diagnosis:	Date of last treatment	
☐ Monitoring: (for follow-up samples)	☐ Other:	
G-Banded Karyotyping Bone Marrow (required sample >1.5mL in sodium heparin tube).  ^G-banded karyotyping on bone marrow.		
Peripheral blood. (required sample 5-10 mL blood in sodium heparin). ONLY PROCESSED FOR:  ^G-banded karyotyping for acute leukemia with peripheral blood blast count >20% (marrow inadequate)  ^G-banded karyotyping for Myelofibrosis  ^G-banded karyotyping to confirm a constitutional abnormality detected on bone marrow karyotype		
Other - REQUIRES LABORATORY APPROVAL – email <u>ca</u>	ancercytogenetics@uhn.ca	
Optical Genome Mapping  Eosinophilia Panel (B/M) – Peripheral Blood or Bone Marrow with Elevated Eosinophils (≥ 10% nucleated cells)  □ PDGFRA / PDGFRB / FGFR1 / PCM1 / JAK2 / ABL1 / ETV6 / FLT3 (expanded gene panel)		
Fluorescence in situ Hybridization (FISH)		
Chronic Myelogenous Leukemia (B/M)  □ ^BCR::ABL1 (only for molecular negative)	FISH for Lymphoid Disorders (continued)  Large B-Cell Lymphoma Panel (B/M/C/P)  ^Reflex Panel (BCL2 and BCL6 only when MYC	
FISH for Plasma Cell Neoplasms  Plasma Cell Neoplasms with CD138 Cell Enrichment  (Magnetic separation requires ≥ 1mL marrow aspirate  If other tests are requested, e.g. karyotype, please submit an additional 1.5-2mL of aspirate in a separate tube.) (M)  ^Multiple Myeloma Panel (or Amyloidosis)	MIYC ONLY	
FISH for Lymphoid Disorders Chronic Lymphocytic Leukemia (B/M)	Anaplastic large cell lymphoma (B/M/P)  ^ALK  MALT lymphoma (B/M/C/P)	
^CLL FISH Panel (WBC > 5x10 <sup>9</sup> cells/mL)	□ ^MALT1	
□ diagnostic	Mantle cell lymphoma (B/M/C/P)	
□ <b>follow up</b> Indicates FISH validation status by sample type: <b>B</b> = Blood, <b>M</b>	□ ^CCND1/IGH t(11;14)(q13;q32) = Marrow, P = Paraffin (surgical or cytology slides), C = Cytospin	
^ indicates a test that will be billed to the referri	ng hospital, laboratory, physician or medical group.	